STRO
Sutro Biopharma
14.30$
-6.9%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -198.0% | 12.4% | -497.7% | 36.8% | -757.2% | -484.4% | -390.2% | -70.2% | -394.0% | -227.0% | -291.0% | -389.2% | -317.7% | |
| 10.3% | 1.5% | 13.5% | 7.0% | 21.1% | 12.6% | 10.9% | 3.0% | 19.6% | 13.9% | 8.8% | 12.8% | 13.3% | |
| 35.5% | 5.5% | 46.6% | 24.0% | 76.8% | 39.9% | 31.8% | 8.3% | 16.0% | 14.2% | 10.8% | 20.4% | 14.8% | |
| 22.1% | -19.0% | -127.7% | 188.2% | -83.6% | -106.3% | -52.6% | -79.3% | 48.0% | 40.2% | -116.7% | -140.0% | -46.8% | |
| 1.9% | 1.3% | 3.4% | 2.9% | 9.7% | 7.2% | 6.7% | 0.1% | 2.6% | 1.6% | 0.1% | 0.0% | 1.0% | |
| -673.7% | -20.7% | 492.8% | -312.7% | 1,728.8% | 590.8% | -93.4% | 4.0% | 412.6% | 160.6% | -311.7% | 196.8% | 71.7% | |
| -0.2% | 0.4% | -2.9% | -0.1% | 4.4% | -0.2% | – | -0.1% | – | – | – | 1.6% | – | |
| – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | |
| -33.9% | -2.7% | -26.4% | 375.4% | 11.9% | -0.2% | 0.4% | -0.1% | 1.1% | -0.5% | 709.7% | -4.2% | 224.7% | |
| -905.6% | -11.0% | -31.1% | 99.5% | 983.5% | 106.2% | -483.2% | -66.2% | 19.6% | -66.9% | 107.1% | -196.6% | -21.2% | |
| -199.9% | 11.1% | -501.1% | 33.8% | -766.9% | -491.6% | -396.9% | -70.3% | -396.6% | -228.5% | -291.1% | -389.2% | -318.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.